Indication
Down syndrome
Aliases
Down Syndrome
22 clinical trials
42 products
6 drugs
Clinical trial
Exploratory Phosphoproteomic Study to Discover DYRK1A-Dependent Blood Biomarkers in TriSomy 21 CarriersStatus: Recruiting, Estimated PCD: 2024-09-01
Product
Blood sampleProduct
PlaceboProduct
AEF0217Clinical trial
A Double-blind, Randomized, Placebo-controlled, 4-week, Phase 1/2 Trial in Young Adult Participants With Down Syndrome to Assess the Safety, Tolerability, Plasma Exposure, and Preliminary Indications of Pharmacodynamic Activity of AEF0217Status: Recruiting, Estimated PCD: 2024-05-01
Clinical trial
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)Status: Active (not recruiting), Estimated PCD: 2019-03-31
Drug
cyclophosphamideProduct
CytarabineProduct
DexamethasoneProduct
DoxorubicinProduct
Leucovorin CalciumProduct
MercaptopurineProduct
MethotrexateProduct
PegaspargaseProduct
ThioguanineDrug
VincristineClinical trial
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)Status: Recruiting, Estimated PCD: 2029-06-30
Product
AsparaginaseProduct
BlinatumomabProduct
PrednisoloneProduct
PrednisoneClinical trial
A Phase 1 and Pharmacokinetic Study of Uproleselan (GMI-1271, NSC #801708) in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia Myelodysplastic Syndrome or Mixed Phenotype Acute Leukemia That Expresses E-Selectin Ligand on the Cell Membrane and is in Second or Greater Relapse or That is Refractory to Relapse TherapyStatus: Recruiting, Estimated PCD: 2024-12-31
Product
FludarabineDrug
mFOLFOX6Product
UproleselanClinical trial
Effect of Pulsatile GnRH Therapy on Cognition in Down Syndrome: Randomized Placebo Control StudyStatus: Recruiting, Estimated PCD: 2028-12-01
Product
GnRHProduct
0.9% NaClClinical trial
Safety and Efficacy of Tofacitinib for Immune Skin Conditions in Down SyndromeStatus: Recruiting, Estimated PCD: 2024-08-01
Product
TofacitinibClinical trial
Randomized Control Trial of Oxygen Therapy in Children and Adolescents With Down Syndrome and Obstructive Sleep ApneaStatus: Recruiting, Estimated PCD: 2027-08-31
Product
OxygenClinical trial
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied DrugsStatus: Recruiting, Estimated PCD: 2024-05-01
Product
POP02Clinical trial
Phase II Trial to Evaluate Safety and Efficacy of GM-CSF /Sargramostim in Down SyndromeStatus: Recruiting, Estimated PCD: 2026-09-01
Product
SargramostimClinical trial
Fluoxetine Treatment of Depression in Adults With Down SyndromeStatus: Recruiting, Estimated PCD: 2024-10-01
Product
FluoxetineProduct
SalineClinical trial
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down SyndromeStatus: Active (not recruiting), Estimated PCD: 2024-06-30
Product
DaunorubicinProduct
EtoposideProduct
MitoxantroneClinical trial
Mechanistic Investigation of Therapies for Down Syndrome Regression DisorderStatus: Recruiting, Estimated PCD: 2026-12-01
Product
LorazepamProduct
Intravenous immunoglobulinClinical trial
Guanfacine for Hyperactivity in Children With Down Syndrome (HYPEbeGONE_DS)Status: Not yet recruiting, Estimated PCD: 2025-11-01
Product
Guanfacine HydrochlorideDrug
VarlilumabClinical trial
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First RelapseStatus: , Estimated PCD: 2028-06-30
Product
HydrocortisoneDrug
DocetaxelDrug
T-VECClinical trial
Medications for Obstructive Sleep Apnea to Improve Cognition in Children With Down SyndromeStatus: Recruiting, Estimated PCD: 2025-08-01
Product
Atomoxetine and OxybutyninClinical trial
Cholinergic Integrity in Down Syndrome in Association With Aging, Alzheimer's Disease Pathology, and CognitionStatus: Recruiting, Estimated PCD: 2024-08-28
Product
FEOBVClinical trial
Phase II Multicenter 16-Week Randomized Double Blind Placebo-Controlled Evaluation of the Efficacy, Tolerability and Safety of Memantine Hydrochloride on Enhancing the Cognitive Abilities of Adolescents and Young Adults With Down SyndromeStatus: Completed, Estimated PCD: 2020-07-22
Product
MemantineClinical trial
Use of Liquid Stable Levothyroxine in Trisomy 21 Pediatric PatientsStatus: Terminated, Estimated PCD: 2021-11-01
Product
Tirosint-SOLProduct
LevothyroxineClinical trial
Sensitivity of the NIH Toolbox Cognition Battery to Stimulant Treatment in Intellectual DisabilitiesStatus: , Estimated PCD: 2025-09-29
Product
MethylphenidateClinical trial
Evaluating Assessment and Medication Treatment of ADHD in Children With Down SyndromeStatus: Recruiting, Estimated PCD: 2025-09-30
Product
Quillivant XRClinical trial
A Phase 2 Double Blind Placebo Controlled Study on the Efficacy of Bumetanide for Cognitive Improvement in Children and Adolescents With Down SyndromeStatus: Recruiting, Estimated PCD: 2025-12-30
Product
Bumetanide